$\Box$ 

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number:

0.5

Estimated average burden

hours per response:

| FICIAL | OWNERSHIP |  |
|--------|-----------|--|
|        |           |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

## STATEMENT OF CHANGES IN BENE

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  SIGMA TAU INTERNATIONAL SA  (Lipst)  (Hiddle) |   |  |   | 2. Issuer Name and Ticker or Trading Symbol<br><u>QUESTCOR PHARMACEUTICALS INC</u> [ qsc _ ] |  |  |  |                                   |   |                       |  | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director X 10% Owner<br>Officer (give title Other (specify<br>below) below) |                                      |   |  |                                      |   |
|---|---|--|---|--|--|--|--|-----------------------------------|---|-----------------------|--|---|--------------------------------------|---|--|--------------------------------------|---|
| (Last)<br>18 AVEN   |   | First)<br>. PORTE NEUV                     | (Middle)<br>E   |  |  | 3. Date of Earliest Transaction (Month/Day/Year)<br>03/08/2005 |  |                                   |   |                       |  |   | below)                               |   | Del  | uw)                                  |   |
| (Street)<br>LUXEMI  | BOURG 1   | N4   | L-2227  |  | 4. If Amendment, Date of Original Filed (Month/Day/Year) |  |  |                                   |   |                       |  | 6. Individual or Joint/Group Filing (Check Applicable Line)<br>Form filed by One Reporting Person<br>X Form filed by More than One Reporting Person       |                                      |   |  |                                      |   |
| (City)  | (   | State)                                     | (Zip)   |  |  |  |  |                                   |   |                       |  |   |                                      |   |  | j-                                   |   |
|   |   |  | Table I - N   | on-Dei   | rivativ  | ve Securi  | ities Ac   | quire                             | d, Dis                                  | posed of,             | or Bene  | ficially C  | Dwned                                |   |  |                                      |   |
| 1. Title of Security (Instr. 3)   |   | 2. Transaction<br>Date<br>(Month/Day/Year) |   | r) 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Yea                                 |  | 3.<br>Transaction<br>Code (Instr.<br>8)                        |  | 4. Securities A<br>Disposed Of (I | cquired (A) or<br>) (Instr. 3, 4 and 5) |                       | 5. Amount of<br>Securities<br>Beneficially Ow<br>Following Repo                            | ned 🛛 or Indi   | Direct (D)<br>rect (I)               | Indire<br>Benef<br>Owne   | eneficial<br>wnership                        |                                      |   |
|   |   |  |   |  |  |  |  | Code                              | v                                       | Amount                | (A) or<br>(D)  | Price   | Transaction(s)<br>(Instr. 3 and 4)   |   |  | (Instr.                              | . 4)  |
| Common  | Stock, no p   | ar value per shar                          | e   |  |  |  |  |                                   |   |                       |  |   | 8,643,397                            | 7   | D  |                                      |   |
| Common  | Stock, no p   | ar value per shar                          | e   |  |  |  |  |                                   |   |                       |  |   | 1,756,781                            | L   | Ι  | by C                                 | es<br>ctly held<br>llaudio<br>azza. <sup>(1)</sup>  |
| Common  | Stock, no p   | ar value per shar                          | e   |  |  |  |  |                                   |   |                       |  |   | 1,756,782                            | 2   | I  | by P                                 | tly held  |
| Common  | Stock, no p   | ar value per shar                          | e   |  |  |  |  |                                   |   |                       |  |   | 759,493                              |   | I  | by D                                 | ctly held<br>Defiante<br>naceutica  |
| Common  | Stock, no p   | ar value per shar                          | e   |  |  |  |  |                                   |   |                       |  |   | 1,265,822                            | 2   | I  | the<br>Conv<br>Debe<br>held<br>Defia | erlying<br>vertible<br>enture<br>by<br>ante<br>naceutica  |
| Common  | Stock, no p   | ar value per shar                          | e   |  |  |  |  |                                   |   |                       |  |   | 449,100                              |   | I  |                                      | tly held<br>ptafin  |
|   |   |  | Table II  | - Deriv  | vative   | e Securiti   | es Acq   | uired                             | , Disp                                  | osed of, o            | r Benefie  | cially Ov   | vned                                 |   |  |                                      |   |
| Derivative C<br>Security C<br>(Instr. 3) F  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4. 5<br>Transaction S<br>Code (Instr. 0  |  | 5. Number of<br>Securities A<br>or Disposed                    | <b>calls, warrants</b><br>5. Number of Derivativ<br>Securities Acquired (A<br>or Disposed of (D)<br>Instr. 3, 4 and 5) |                                   |   | ercisable and<br>Date | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 3 and 4) |   | Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned | f 10.<br>Owner<br>Form:<br>Direct<br>or Indi | rship<br>(D)                         | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)  |
|   |   |  |   | Code   | v  | (A)  | (D)  | Da<br>Ex                          | te<br>ercisable                         | Expiration<br>Date    | Title  | Amount o<br>Number o<br>Shares  |                                      | Following<br>Reported<br>Transaction(<br>(Instr. 4)               |  | (I) (Instr. 4)                       |   |
| Convertible<br>Debenture  | \$1.58  | 03/08/2005                                 |   | J <sup>(2)</sup>   |  |  | \$2,000,0  | 00                                | (3)                                     | 03/15/2005            | Common<br>Stock, no<br>par value<br>per share  | 1,265,82  | \$2,000,000                          | \$0   | I  |                                      | The<br>Convertible<br>Debenture is<br>directly held<br>by Defiante<br>Farmaceutica<br>L.d.A. <sup>(1)</sup> |
| Convertible<br>Debenture  | \$1.58  | 03/08/2005                                 |   | J <sup>(2)</sup>   |  | \$2,000,000  |  |                                   | (3)                                     | 04/15/2005            | Common<br>Stock, no<br>par value<br>per share  | 1,265,82  | 22 <b>\$</b> 2,000,000               | \$2,000,000   | I  |                                      | The<br>Convertible<br>Debenture is<br>directly held<br>by Defiante<br>Farmaceutica<br>L.d.A. <sup>(1)</sup> |
|   |   | Reporting Person*                          | IAL SA  |  |  |  |  |                                   |   |                       |  |   |                                      |   |  |                                      |   |

(First)

(Middle)

| 18 AVENUE DE LA PORTE NEUVE   |   |          |  |  |  |  |
|---|---|----------|--|--|--|--|
| (Street)<br>LUXEMBOURG  | N4  | L-2227   |  |  |  |  |
| (City)  | (State)   | (Zip)    |  |  |  |  |
| 1. Name and Address of R<br>SIGMA TAU FIN                             |   |          |  |  |  |  |
| (Last)<br>VIA SUDAFRICA 20<br>144                                     | (First)   | (Middle) |  |  |  |  |
| (Street)<br>ROME ITALY  |   |          |  |  |  |  |
| (City)  | (State)   | (Zip)    |  |  |  |  |
| 1. Name and Address of R<br>DEFIANTE FAR                              | reporting Person <sup>*</sup> <u>MACEUTICA LD</u> | A        |  |  |  |  |
| (Last)<br>RUA DOS FERREIR   | (First)<br>OS,260                                 | (Middle) |  |  |  |  |
| (Street)<br>FUNCHAL<br>MADEIRA  | S1  | 9000-082 |  |  |  |  |
| (City)  | (State)   | (Zip)    |  |  |  |  |
| 1. Name and Address of R<br><u>APTAFIN S P A</u>                      | eporting Person*                                  |          |  |  |  |  |
| (Last)<br>VIALE SHAKESPEA   | (First)<br>ARE 47                                 | (Middle) |  |  |  |  |
| (Street)<br>ROME  | L6  | 00144    |  |  |  |  |
| (City)  | (State)   | (Zip)    |  |  |  |  |
| 1. Name and Address of R<br>CAVAZZA CLAU                              |   |          |  |  |  |  |
| (Last)<br>VIA SUDAFRICA 2(  | (First)<br>)                                      | (Middle) |  |  |  |  |
| (Street)<br>ROME ITALY  | L6  | 00000    |  |  |  |  |
| (City)  | (State)   | (Zip)    |  |  |  |  |
| 1. Name and Address of Reporting Person <sup>*</sup><br>CAVAZZA PAOLO |   |          |  |  |  |  |
| (Last)<br>VIA TESSERETE, 10   | (First)   | (Middle) |  |  |  |  |
| (Street)<br>LUGANO  | V8  | V8       |  |  |  |  |
| (City)  | (State)   | (Zip)    |  |  |  |  |

Explanation of Responses:

1. Sigma-Tau Finanziaria S.p.A. owns 100% of the capital stock of Sigma-Tau International S.A. (f/k/a Sigma-Tau Finance Holding S.A.) and 58% of the capital stock of Defiante Farmaceutica L.d.A. Sigma-Tau International S.A. owns 42% of the capital stock of Defiante Farmaceutica L.d.A. Claudio Cavazza owns, directly and indirectly, 60% of Sigma-Tau Finanziaria S.p.A. and Paolo Cavazza owns, directly and indirectly, 40% of Sigma-Tau Finanziaria S.p.A. Paolo Cavazza owns, directly and indirectly, 100% of Aptafin S.p.A.

2. Amendment of outstanding 8% Convertible Debenture resulting in deemed cancellation of the debenture and issuance of a replacement debenture. The 8% Convertible Debenture was originally issued in March 2002 in the principal amount of \$2,000,000 with a maturity date of March 15, 2005. On March 8, 2005, the maturity date of the debenture was extended until April 15, 2005.

3. Defiante Farmaceutica L.d.A., the holder of the Convertible Debenture, may convert all or any portion of the debenture into Common Stock, no par value per share, at any time prior to the maturity date.

| <u>Maurizio Terenzi, Attorney-in-fact</u><br><u>for Sigma-Tau International S.A.</u> | <u>03/09/2005</u> |
|--|-------------------|
| <u>Maurizio Terenzi, Attorney-in-fact</u><br><u>for Sigma-Tau Finanziari S.p.A.</u>  |                   |
| <u>Maurizio Terenzi, Attorney-in-fact</u><br>for Defiante Farmaceutica L.D.A.        | <u>03/09/2005</u> |
| <u>Maurizio Terenzi, Attorney-in-fact</u>  |                   |

for Aptafin S.p.A.03/09/2005Maurizio Terenzi, Attorney-in-fact<br/>for Claudio Cavazza03/09/2005Maurizio Terenzi, Attorney-in-fact<br/>for Paolo Cavazza03/09/2005

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.